Viatris Valuation
Is VTRS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VTRS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VTRS * (MX$191.5) is trading below our estimate of fair value (MX$610.91)
Significantly Below Fair Value: VTRS * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VTRS *?
Other financial metrics that can be useful for relative valuation.
What is VTRS *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$13.74b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2x |
Enterprise Value/EBITDA | 6.4x |
PEG Ratio | 16x |
Price to Sales Ratio vs Peers
How does VTRS *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.6x | ||
LAB B Genomma Lab Internacional. de | 0.9x | 8.0% | Mex$15.2b |
000538 Yunnan Baiyao GroupLtd | 2.5x | 7.5% | CN¥99.9b |
3692 Hansoh Pharmaceutical Group | 9.5x | 8.9% | HK$103.5b |
SDZ Sandoz Group | 1.5x | 4.8% | CHF13.2b |
VTRS * Viatris | 0.9x | -1.2% | Mex$13.7b |
Price-To-Sales vs Peers: VTRS * is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (3.6x).
Price to Earnings Ratio vs Industry
How does VTRS *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Sales vs Industry: VTRS * is good value based on its Price-To-Sales Ratio (0.9x) compared to the Global Pharmaceuticals industry average (2.4x).
Price to Sales Ratio vs Fair Ratio
What is VTRS *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.9x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate VTRS *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$191.50 | Mex$210.97 +10.2% | 7.0% | Mex$238.28 | Mex$187.22 | n/a | 9 |
Apr ’25 | Mex$196.05 | Mex$206.07 +5.1% | 7.0% | Mex$232.74 | Mex$182.87 | n/a | 9 |
Mar ’25 | Mex$218.00 | Mex$204.34 -6.3% | 9.6% | Mex$239.37 | Mex$170.98 | n/a | 9 |
Feb ’25 | Mex$201.50 | Mex$202.00 +0.2% | 11.1% | Mex$241.12 | Mex$172.23 | n/a | 9 |
Jan ’25 | n/a | Mex$197.27 0% | 12.7% | Mex$237.72 | Mex$152.82 | n/a | 9 |
Dec ’24 | n/a | Mex$199.62 0% | 13.5% | Mex$240.67 | Mex$154.71 | n/a | 8 |
Nov ’24 | Mex$151.00 | Mex$213.20 +41.2% | 13.9% | Mex$254.30 | Mex$163.48 | n/a | 8 |
Oct ’24 | Mex$159.76 | Mex$220.24 +37.9% | 11.2% | Mex$261.03 | Mex$174.02 | n/a | 9 |
Sep ’24 | n/a | Mex$212.96 0% | 12.0% | Mex$256.46 | Mex$170.98 | n/a | 9 |
Aug ’24 | Mex$177.00 | Mex$210.60 +19.0% | 12.0% | Mex$255.90 | Mex$170.60 | n/a | 9 |
Jul ’24 | Mex$172.50 | Mex$216.08 +25.3% | 11.9% | Mex$259.09 | Mex$172.73 | n/a | 10 |
Jun ’24 | n/a | Mex$227.50 0% | 11.8% | Mex$269.64 | Mex$179.76 | n/a | 9 |
May ’24 | Mex$165.99 | Mex$227.50 +37.1% | 11.8% | Mex$269.64 | Mex$179.76 | n/a | 9 |
Apr ’24 | Mex$170.00 | Mex$251.38 +47.9% | 17.3% | Mex$338.82 | Mex$188.23 | Mex$196.05 | 11 |
Mar ’24 | n/a | Mex$244.59 0% | 16.7% | Mex$329.37 | Mex$182.98 | Mex$218.00 | 12 |
Feb ’24 | Mex$215.00 | Mex$250.45 +16.5% | 16.9% | Mex$335.18 | Mex$186.21 | Mex$201.50 | 12 |
Jan ’24 | Mex$210.00 | Mex$257.14 +22.4% | 18.2% | Mex$348.72 | Mex$193.73 | n/a | 11 |
Dec ’23 | n/a | Mex$257.14 0% | 18.2% | Mex$348.72 | Mex$193.73 | n/a | 11 |
Nov ’23 | n/a | Mex$250.03 0% | 22.4% | Mex$358.74 | Mex$179.37 | Mex$151.00 | 11 |
Oct ’23 | n/a | Mex$275.38 0% | 27.2% | Mex$428.37 | Mex$183.59 | Mex$159.76 | 10 |
Sep ’23 | Mex$197.00 | Mex$277.49 +40.9% | 26.9% | Mex$425.35 | Mex$182.29 | n/a | 10 |
Aug ’23 | Mex$202.00 | Mex$283.20 +40.2% | 28.7% | Mex$427.85 | Mex$183.37 | Mex$177.00 | 10 |
Jul ’23 | Mex$208.00 | Mex$288.60 +38.7% | 28.4% | Mex$432.90 | Mex$185.53 | Mex$172.50 | 10 |
Jun ’23 | Mex$239.00 | Mex$293.94 +23.0% | 24.7% | Mex$426.93 | Mex$203.30 | n/a | 12 |
May ’23 | Mex$205.00 | Mex$284.28 +38.7% | 25.4% | Mex$415.30 | Mex$197.76 | Mex$165.99 | 12 |
Apr ’23 | Mex$205.00 | Mex$293.94 +43.4% | 25.7% | Mex$437.30 | Mex$208.24 | Mex$170.00 | 13 |
Analyst Forecast: Target price is less than 20% higher than the current share price.